Notably, up to 50% of LCH patients carry the BRAFV600E mutation, alongside other activating mutations in the BRAF, MAP2K1, ARAF, ERBB3, NRAS, and KRAS genes [4, 7]. Here, MAP2K1 is linked to Langerhans cell histiocytosis.